The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags

Journal of Oncology Pharmacy Practice

Volumn 12, Issue 2, 2006, Pages 113-118

  Gilbar, Peter J ^a   Carrington, Christine V ^b  

^a Toowoomba Health Services   (Australia)

^b MATER HOSPITAL   (Australia)

Author keywords

Extravasation; Inadvertent intrathecal administration; Mini bags; Syringes; Vinblastine; Vinca alkaloid; Vincristine; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; VINCA ALKALOID;

ARTICLE; AUSTRALIA; COMPARATIVE STUDY; CONTRAST MEDIUM EXTRAVASATION; HEALTH SURVEY; HUMAN; INCIDENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SYRINGE;

ANTINEOPLASTIC AGENTS; AUSTRALIA; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HEALTH SURVEYS; HUMANS; INCIDENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SYRINGES; VINCA ALKALOIDS;

EID: 34250017555     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206070448     Document Type: Article

References (26)

1. Mullin S, Beckwith MC. Prevention and management of antineoplastic extravasation injury. Hosp Pharm 2000;35:57-74.
2. Schrijvers DL. Extravasation: A dreaded complication of chemotherapy. Ann Oncol 2003;14:26-30.
3. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858-862.
4. Kassner E. Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 2000;17:135-148.
5. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990;4:41-60.
6. Schochet SS, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 1968;27:645-658.
7. Fernandez CV, Esau R, Hamilton D, et al. Intrathecal vincristine: An analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention. J Ped Hemat Oncol 1998; 20: 587 - 590.
8. Womer RB, Tracy E, Soo-Hoo W, et al. Multidisciplinary systems approach to chemotherapy safety: Rebuilding processes and holding the gains. J Clin Oncol 2002;20:4705-4712.
9. Gilbar PJ, Carrington CV. Preventing intrathecal administration of vincristine. Med J Aust 2004; 181: 464 - 464.
10. Gilbar P, Carrington C. Inadvertent intrathecal administration of vincristine. J Pharm Pract Res 2004;34:159-159.
11. Gilbar P, Dooley M, Brien J. Inadvertent intrathecal administration of vincristine: Are we fulfilling our roles as oncology pharmacists? J Oncol Pharm Pract 2004;10:187-189.
12. Stefanou A, Dooley M. Simple method to eliminate the risk of inadvertent intrathecal vincristine administration. J Clin Oncol 2003;21:2044-2047.
13. Woods K. The prevention of intrathecal medication errors. A report to the Chief Medical Officer. Department of Health, London, 2001.
14. UK Department of Health. Updated guidance of the safe administration of intrathecal chemotherapy. Health Service Circular 2003/010, 2003.
15. Meggs WJ, Hoffman RS. Fatality resulting from intraventricular vincristine administration. J Toxicol Clin Toxicol 1998;36:243-246.
16. Alcaraz A, Rey C, Concha A, Medina A. Intrathecal vincristine: Fatal myeloencephalopathy despite cerebrospinal fluid perfusion. J Toxicol Clin Toxicol 2002;40:557-561.
17. Schulmeister L, Camp-Sorrell D. Chemotherapy extravasation from implanted ports. Oncol Nurs Forum 2000;27:531-540.
18. Cox K, Stuart-Harris, Abdini G, et al. The management of cytotoxic-drug extravasation: Guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 1988;148:185-189.
19. Bingham JM, Dooley MJ. EXTRA - EXtravasation Treatment Record dAtabase: a database to record and review cytotoxic drug extravasation events. Aust J Hosp Pharm 1998;28:89-93.
20. Moreno de Vega MJ, Dauden E, Abajo P, et al. Skin necrosis from extravasation of vinorelbine. J Eur Acad Dermatol Venereol 2002;16:488-490.
21. Vassilomanolakis M, Koumakis G, Barbounis V, et al. Prevention of vinorelbine phlebitis with cimetidine. Support Care Cancer 2001;19:108-111.
22. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine®). Oncol Nurs Forum 1995;22:707-710.
23. Hadaway LC. Preventing and managing peripheral extra-vasation. Nursing 2004;34:66-67.
24. Boyle DM, Engelking C. Vesicant extravasation: Myths and realities. Oncol Nurs Forum 1995;22:57-67.
25. Hadaway LC. Preventing extravasation from a central line. Nursing 2004;34:22-23.
26. Camp-Sorrell D. Developing extravasation protocols and monitoring outcomes. J Intraven Nurs 1998;24:232-239.